Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jean Paul Nicandro
Observed names:
J. Nicandro,
J. P. Nicandro,
J.P. Nicandro,
Jean Paul A. Nicandro
Institutions:
Prometheus Biosciences (United States),
Allergan (United States)
Observed institutions:
University of California, San Francisco,
Prometheus Biosciences (United States),
VA Southern Nevada Healthcare System,
Allergan (United States)
OpenAlex ID:
A5077632073
Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea‐predominant IBS
2012
·
F. Cremonini
, J. P. Nicandro
, et al.
·
Alimentary Pharmacology & Therapeutics
·
71
PDF
A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program
2013
·
Kenneth Tong
, Jean Paul Nicandro
, et al.
·
Therapeutic Advances in Gastroenterology
·
60
Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint
2018
·
Brian E. Lacy
, Jean Paul Nicandro
, et al.
·
Therapeutic Advances in Gastroenterology
·
54
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS
2018
·
Mark Tullman
, Emmanuel Chartier-Kastler
, et al.
·
Neurology
·
33
PDF
Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder
2017
·
David A. Ginsberg
, Marcus J. Drake
, et al.
·
The Journal of Urology
·
25
Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome
2018
·
Kevin W. Olden
, William D. Chey
, et al.
·
Current Medical Research and Opinion
·
19
In vivo Effect of I'm-Yunity™ on Hepatic Cytochrome P450 3A4
2007
·
Jean Paul A. Nicandro
, Candy Tsourounis
, et al.
·
Journal of Herbal Pharmacotherapy
·
14
Evaluation of treatment continuation with alosetron by IBS-D severity criteria
2012
·
Jean Paul Nicandro
, Paul Shin
, et al.
·
Current Medical Research and Opinion
·
7
9-Year Evaluation of Temporal Trends in Alosetron Postmarketing Safety Under the Risk Management Program
2012
·
Lin Chang
, Kenneth Tong
, et al.
·
The American Journal of Gastroenterology
·
1
Tu1386 Alosetron Treatment Reduced Health Care Utilization and Improved Symptoms More Effectively Than Traditional Therapy in Women With Severe IBS-D
2012
·
William D. Chey
, Reshma Shringarpure
, et al.
·
Gastroenterology
·
1
M1058 Alosetron is Associated With Improvements in Treatment Satisfaction and Quality of Life
2010
·
Jean Paul A. Nicandro
, Paul Shin
, et al.
·
Gastroenterology
·
1
Sa1561 – Biomarkers and Clinical Characteristics Associated with Nonalcoholic Steatohepatitis Fibrosis Progression: Centaur Study
2019
·
Nicolas Lanthier
, Johannes Kluwe
, et al.
·
Gastroenterology
SAT-351-Biomarkers and clinical characteristics associated with nonalcoholic steatohepatitis fibrosis progression in the CENTAUR study
2019
·
Nicolas Lanthier
, Johannes Kluwe
, et al.
·
Journal of Hepatology
Mp31-01 Long-term Safety and Efficacy of Ser120 1.5 Mcg in Patients With Nocturia: Results From a 2-year Open-label Extension Study
2017
·
Scott MacDiarmid
, J.P. Nicandro
, et al.
·
The Journal of Urology
Efficacy and safety of onabotulinumtoxina 100 U for treatment of urinary incontinence due to neurogenic detrusor overactivity in noncatheterizing multiple sclerosis patients
2016
·
Francisco Cruz
, Pierre Denys
, et al.
·
Toxicon
Consistent and durable improvements in quality of life with long-term onabotulinumtoxina treatment in patients with overactive bladder
2016
·
Emmanuel Chartier-Kastler
, Albert Kaufmann
, et al.
·
Toxicon
Efficacy and safety of onabotulinumtoxin A 100U for treatment of urinary incontinence due to neurogenic detrusor overactivity in non-catheterising multiple sclerosis patients
2016
·
P. Denys
, V. Keppenne
, et al.
·
The French Journal of Urology
Mp74-07 Consistent and Durable Improvements in Quality of Life With Long-term Onabotulinumtoxina Treatment in Patients With Overactive Bladder
2016
·
David Ginsberg
, Marcus Drake
, et al.
·
The Journal of Urology
PDF
Risk of Serious Adverse Events With Alosetron is Similar to or Less Than That Associated With Other Drugs Prescribed for Chronic GI Disorders
2014
·
Susan Lucak
, Jean Paul Nicandro
, et al.
·
The American Journal of Gastroenterology
Tu1075 Effects on Health Outcomes With Alosetron in Clinical Practice: Results From a Multicenter Observational Study
2013
·
Brian E. Lacy
, Jean Paul A. Nicandro
, et al.
·
Gastroenterology
Physician and Patient Perceptions of Treatment Outcome After 12 Weeks on Alosetron: Results of a Multi-Center Observational Study
2012
·
Brian Lacy
, Reshma Shringarpure
, et al.
·
The American Journal of Gastroenterology
Changes in Quality of Life and Daily Activities Are Associated with Symptom Improvement in Irritable Bowel Syndrome: Clinically Meaningful Effects and Minimal Sample Sizes for Future Clinical Trials
2011
·
Filippo Cremonini
, Jean Paul Nicandro
, et al.
·
The American Journal of Gastroenterology
Disability or Restriction of Daily Activities is the Most Common Indicator of Disease Severity in Female Patients with Severe IBS-D: An Analysis of the Alosetron Patient Survey
2010
·
Jean Paul Nicandro
, Pat Tennis
, et al.
·
The American Journal of Gastroenterology
Alosetron Treatment Led to Fewer Physician Contacts and Fewer Days of Lost Work Productivity Compared to Treatment with Traditional Therapy for Diarrhea-Predominant IBS (IBS-D)
2010
·
Kevin Olden
, Reshma Shringarpure
, et al.
·
The American Journal of Gastroenterology
T1064 One-Year Treatment Continuation With Alosetron is High Irrespective of IBS-D Severity
2010
·
Jean Paul A. Nicandro
, Pat Tennis
, et al.
·
Gastroenterology
Show more works
View as search
Works count:
25
Citation count:
286
H-index:
7
I10-index:
7
Year
Topic
Type